Superficial CD34-positive fibroblastic tumor: report of two cases and review of the literatures
10.3760/cma.j.cn114453-20240820-00214
- VernacularTitle:浅表CD34阳性纤维母细胞肿瘤2例及文献复习
- Author:
Rui ZHANG
1
;
Zheren SU
;
Junsang LONG
;
Renrong LYU
;
Jianhai BI
;
Ran HUO
Author Information
1. 山东大学齐鲁医学院，济南 250063
- Publication Type:Journal Article
- Keywords:
Skin neoplasms;
Fibroblastic tumors;
CD34-positive;
Immunohistochemistry;
Diagnosis, differential
- From:
Chinese Journal of Plastic Surgery
2025;41(1):81-86
- CountryChina
- Language:Chinese
-
Abstract:
This paper reported the clinical manifestations, pathological features, immunophenotype and follow-up of two patients with superficial CD34-positive fibroblastic tumor (SCPFT), who were admitted to Shandong Provincial Hospital in 2022 and 2023, and discussed the relevant literatures. The two patients, aged 43 and 20 years old, were both male. Their tumors were located in the perineum and the back of left shoulder, respectively. Both presented as single slow-growing subcutaneous masses with a course typically measured in years, accompanied by mild tenderness but without pain or pruritus. Microscopically, spindled to epithelioid cells and pleomorphous nuclear cells arranged in cellular fascicles and solid sheets were the main findings. Immunophenotypically, positive expression of CD34 was found in both cases. Extended resection ensured negative marginal and basal margins for both cases. No recurrence was observed after 22 and 12 months of follow-up, respectively. Clinical features, pathology, and differential diagnosis were discussed and summarized through a review of relevant literature. SCPFT is a novel type of fibroblastic tumor categorized as a low-grade malignant soft tissue tumor with unique pathological and biological characteristics that is relatively rare clinically. Routine resection may lead to recurrence; therefore, long-term follow-up is necessary. The combination of morphological characteristics and immunohistochemistry is helpful to diagnosis. It is important to differentiate this disease from other tumors to avoid misdiagnosis or mistreatment.
